文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

GPR65 有助于构建脑胶质瘤中的免疫抑制微环境。

GPR65 contributes to constructing immunosuppressive microenvironment in glioma.

机构信息

Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 300000, China.

Laboratory of Neuro-oncology, Tianjin Neurological Institute, Tianjin, China.

出版信息

Neurosurg Rev. 2024 Aug 10;47(1):417. doi: 10.1007/s10143-024-02633-4.


DOI:10.1007/s10143-024-02633-4
PMID:39123083
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11315802/
Abstract

Glioma, especially glioblastoma patients, present highly heterogeneous and immunosuppressive microenvironment, leading to their poor response to treatment and survival. Targeting the tumor microenvironment is considered a promising therapeutic strategy. M2 macrophages are highly infiltrated in glioma tissue, even up to 50% of the total number of bulk tissue cells. Here, we identified GPR65 as the hub gene of the M2 macrophage-related module in glioma through WGCNA analysis. The expression and prognosis analysis suggested that GPR65 was positively correlated with the malignancy and poor prognosis of glioma, and the heterogeneity analysis found that GPR65 was highly expressed in the vascular proliferation area of glioma, which matched the spatial expression characteristics of M2 macrophages. We further verified that GPR65 was highly expressed in macrophages but not tumor cells in the glioma microenvironment by single-cell data analysis and immunofluorescence. Most importantly, we found that inhibition of GPR65 was sufficient to reduce macrophages' polarization response to glioma cell and break the malignant cooperation with glioma cells. Our study reports the expression characteristics and malignant behavior of GPR65 in the glioma microenvironment, which provides a new alternative target of treatment to glioma microenvironment.

摘要

胶质瘤,尤其是胶质母细胞瘤患者,存在高度异质性和免疫抑制的微环境,导致其对治疗的反应和生存较差。靶向肿瘤微环境被认为是一种有前途的治疗策略。M2 巨噬细胞高度浸润于胶质瘤组织中,甚至高达总组织细胞数的 50%。在这里,我们通过 WGCNA 分析鉴定出 GPR65 是胶质瘤中与 M2 巨噬细胞相关模块的枢纽基因。表达和预后分析表明,GPR65 与胶质瘤的恶性程度和预后不良呈正相关,异质性分析发现 GPR65 在胶质瘤的血管增殖区域高表达,与 M2 巨噬细胞的空间表达特征相匹配。我们通过单细胞数据分析和免疫荧光进一步证实,GPR65 在胶质瘤微环境中的巨噬细胞中高表达,但在肿瘤细胞中不表达。最重要的是,我们发现抑制 GPR65 足以减少巨噬细胞对胶质瘤细胞的极化反应,并打破与胶质瘤细胞的恶性合作。我们的研究报告了 GPR65 在胶质瘤微环境中的表达特征和恶性行为,为胶质瘤微环境提供了一个新的治疗替代靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71ac/11315802/51c7be0b1d20/10143_2024_2633_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71ac/11315802/034b258b1cb9/10143_2024_2633_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71ac/11315802/11bb10ea0378/10143_2024_2633_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71ac/11315802/eb8efb5fbdcb/10143_2024_2633_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71ac/11315802/74d58cff2c75/10143_2024_2633_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71ac/11315802/51c7be0b1d20/10143_2024_2633_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71ac/11315802/034b258b1cb9/10143_2024_2633_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71ac/11315802/11bb10ea0378/10143_2024_2633_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71ac/11315802/eb8efb5fbdcb/10143_2024_2633_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71ac/11315802/74d58cff2c75/10143_2024_2633_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71ac/11315802/51c7be0b1d20/10143_2024_2633_Fig5_HTML.jpg

相似文献

[1]
GPR65 contributes to constructing immunosuppressive microenvironment in glioma.

Neurosurg Rev. 2024-8-10

[2]
GPR65 sensing tumor-derived lactate induces HMGB1 release from TAM via the cAMP/PKA/CREB pathway to promote glioma progression.

J Exp Clin Cancer Res. 2024-4-4

[3]
Comment on "GPR65 contributes to constructing immunosuppressive microenvironment in glioma".

Neurosurg Rev. 2024-8-28

[4]
HSPA5-mediated glioma hypoxia tolerance promotes M2 macrophage polarization under hypoxic microenvironment.

Int Immunopharmacol. 2025-2-6

[5]
Overexpression of G-protein-coupled receptors 65 in glioblastoma predicts poor patient prognosis.

Clin Neurol Neurosurg. 2018-1

[6]
High expression of SIGLEC7 may promote M2-type macrophage polarization leading to adverse prognosis in glioma patients.

Front Immunol. 2024

[7]
Crosstalk between CD180-overexpression macrophages and glioma cells worsens patient survival through malignant phenotype promotion and immunosuppressive regulation.

Mol Med. 2024-12-20

[8]
COL8A1 is a potential prognostic biomarker associated with migration, proliferation, and tumor microenvironment in glioma.

Exp Cell Res. 2024-6-1

[9]
Integrated bioinformatics analysis and experimental validation reveal the relationship between ALOX5AP and the prognosis and immune microenvironment in glioma.

BMC Med Genomics. 2024-8-21

[10]
Hypoxia promotes glioma-associated macrophage infiltration via periostin and subsequent M2 polarization by upregulating TGF-beta and M-CSFR.

Oncotarget. 2016-12-6

引用本文的文献

[1]
Immunometabolism and oxidative stress: roles and therapeutic strategies in cancer and aging.

NPJ Aging. 2025-7-1

[2]
Whole body and hematopoietic cell-specific deletion of G-protein coupled receptor 65 (GPR65) improves insulin sensitivity in diet-induced obese mice.

Mol Metab. 2025-7

[3]
The Role of Gut Microbiome on Glioblastoma Oncogenesis and Malignant Evolution.

Int J Mol Sci. 2025-3-24

[4]
Understanding Neovascularization in Glioblastoma: Insights from the Current Literature.

Int J Mol Sci. 2025-3-19

本文引用的文献

[1]
Single-cell RNA sequencing identifies critical transcription factors of tumor cell invasion induced by hypoxia microenvironment in glioblastoma.

Theranostics. 2023

[2]
Updates in Glioblastoma Immunotherapy: An Overview of the Current Clinical and Translational Scenario.

Biomedicines. 2023-5-24

[3]
Individual glioblastoma cells harbor both proliferative and invasive capabilities during tumor progression.

Neuro Oncol. 2023-12-8

[4]
Interleukin-10 in cancer immunotherapy: from bench to bedside.

Trends Cancer. 2023-9

[5]
CDYL knockdown reduces glioma development through an antitumor immune response in the tumor microenvironment.

Cancer Lett. 2023-7-28

[6]
Emerging interleukin targets in the tumour microenvironment: implications for the treatment of gastrointestinal tumours.

Gut. 2023-8

[7]
Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor-Initiating Cells.

Cancer Res. 2023-5-15

[8]
Vorinostat decrease M2 macrophage polarization through ARID1A/HDAC6/IL-10 signaling pathway in endometriosis-associated ovarian carcinoma.

Biomed Pharmacother. 2023-5

[9]
Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.

Genome Med. 2023-3-13

[10]
Convection-enhanced delivery of nanoencapsulated gene locoregionally yielding ErbB2/Her2-specific CAR-macrophages for brainstem glioma immunotherapy.

J Nanobiotechnology. 2023-2-20

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索